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Abstract
Germline TSC1 or TSC2 mutations cause Tuberous Sclerosis Complex (TSC), a hamartoma 
syndrome with lung involvement. To explore the potential interaction between TSC1 and KRAS 
activation in lung cancer, mice were generated in which Tsc1 loss and KrasG12D expression occur 
in a small fraction of lung epithelial cells. Mice with combined Tsc1-KrasG12D mutation had 
dramatically reduced tumor latency (median survival 11.6 – 15.6 weeks) in comparison to 
KrasG12D alone mutant mice (median survival 27.5 weeks). Tsc1-Kras G12D tumors showed 
consistent activation of mTORC1, and responded to treatment with rapamycin leading to 
significantly improved survival, while rapamycin had minor effects on cancers in KrasG12D alone 
mice. Loss of heterozygosity for TSC1 or TSC2 was found in 22% of 86 human lung cancer 
specimens. However, none of 80 lung cancer lines studied showed evidence of lack of expression 
of either TSC1 or TSC2 or a signaling pattern corresponding to complete loss. These data indicate 
Tsc1 loss synergizes with Kras mutation to enhance lung tumorigenesis in the mouse, but that this 
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is a rare event in human lung cancer. Rapamycin may have unique benefit for lung cancer patients 
in which TSC1/TSC2 function is limited.
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Introduction
Lung cancer is the leading cause of cancer-related deaths both in the USA and worldwide 
(Jemal et al., 2008; Molina et al., 2008). Non-small cell lung cancer (NSCLC) accounts for 
80% of all cases. In NSCLC, several proto-oncogenes, such as KRAS and EGFR are known 
to be mutated at significant frequency (Thomas et al., 2007; Ding et al., 2008; Molina et al., 
2008). In addition, loss of tumor suppressor gene function is known to occur in NSCLC 
(Weir et al., 2007; Ding et al., 2008). To dissect the role of tumor suppressor genes in lung 
tumorigenesis, we have generated a series of murine models utilizing an activatable 
KrasG12D allele (Jackson et al., 2001), and conditional alleles of several different tumor 
suppressor genes: p53, p16Ink4a, Ink4a/arf, and Lkb1 (Ji et al., 2007). Among these, loss of 
Lkb1 had the most potent effect in accelerating lung tumorigenesis, and led to several 
different histologic subtypes as well as invasion and metastasis (Ji et al., 2007). LKB1 
inactivation also occurs in up to 35% of human lung cancer (Ji et al., 2007; Sanchez-
Cespedes, 2007; Ding et al., 2008). LKB1 is a serine/threonine kinase that has multiple 
targets, including AMPK which phosphorylates and activates the TSC1/TSC2 complex 
(Corradetti et al., 2004; Shaw et al., 2004; Hardie & Sakamoto, 2006).
The TSC1/TSC2 complex is the only known GTPase for Rheb, serving to reduce Rheb-GTP 
levels, and thereby inhibit activation of mTORC1, a protein complex consisting of mTOR, 
RAPTOR, and mLST8 (Guertin & Sabatini, 2007; Huang & Manning, 2008). TSC1 and 
TSC2 are the targets of multiple kinases which regulate the GTPase activity of the complex, 
and thus they function as critical integrators of growth signals within the cell. Loss of either 
TSC1 or TSC2 prevents formation of a functional TSC1/TSC2 complex resulting in 
constitutive activation of mTORC1 and phosphorylation of its downstream targets S6K and 
4E-BP1, with net effects of abnormal translational activation leading to cell growth and 
proliferation (Guertin & Sabatini, 2007; Huang & Manning, 2008).
Germline mutations of TSC1 or TSC2 result in Tuberous Sclerosis Complex (TSC), an 
autosomal dominant tumor suppressor gene syndrome that is characterized by widespread 
hamartoma development (Crino et al., 2006). The pulmonary manifestations of TSC include 
lymphangioleiomyomatosis and multifocal micronodular pneumocyte hyperplasia, although 
lung cancer is rare in TSC patients (Muir et al., 1998; McCormack, 2008).
Since Lkb1 loss synergized with Kras activation to accelerate tumorigenesis in the mouse (Ji 
et al., 2007), we hypothesized that part or all of this effect was due to loss of AMPK 
activation by LKB1, leading to functional inactivation of the TSC1/TSC2 complex and 
downstream mTORC1 activation (Corradetti et al., 2004; Shaw et al., 2004). To examine 
this hypothesis in vivo, we generated a novel lung adenocarcinoma murine model by 
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intercrossing the conditional oncogenic LSL-KrasG12D allele (Jackson et al., 2001) and a 
conditional Tsc1 null allele (Kwiatkowski et al., 2002). Strikingly, homozygous or 
heterozygous loss of Tsc1 dramatically accelerated KrasG12D-driven lung cancer 
development. In addition, the mTORC1 inhibitor rapamycin appeared to have unique benefit 
in inducing tumor regression and extending survival in the Tsc1-KrasG12D mice. We then 
examined the potential role of the TSC1/TSC2 complex in human lung cancer development 
using both direct patient specimens, and a panel of 80 NSCLC cell lines. A significant 
fraction of human lung cancer samples showed evidence of TSC1 or TSC2 LOH, mainly 
TSC1 LOH. However, none of the cell lines showed evidence of complete loss of TSC1 or 
TSC2, suggesting that this event is rare in vivo in patients.
Materials and Methods
Mouse cohorts
Mice bearing the Lox-Stop-Lox-KrasG12D allele were provided by Tyler Jacks, 
Massachusetts Institute of Technology (Jackson et al., 2001). Tsc1L/L mice were generated 
by floxing exons 17 and 18 of the Tsc1 gene, as described previously (Kwiatkowski et al., 
2002). To generate LSL-KrasG12D Tsc1L/L mice, LSL-KrasG12D mice were first crossed with 
Tsc1L/L mice and the progeny LSL-KrasG12D Tsc1L/+ mice were backcrossed to Tsc1L/L 
mice. Due to this breeding scheme, the strain background was mixed for all mice studied. 
Mice were treated with adenoviral Cre (AdCre) by nasal inhalation at 4-7 weeks of age to 
induce KrasG12D expression and/or inactivation of Tsc1L alleles by cleavage at the Lox sites 
in the infected respiratory epithelium. The animals were housed in a pathogen-free 
environment in a barrier facility at Harvard School of Public Health; all animal experiments 
performed were approved by the Institutional Animal Care and Use Committee at Harvard 
Medical School. Mice were terminated when severe dyspnea, weight loss, or other signs of 
morbidity were seen. The logrank test was used to compare the survival of different groups 
of mice.
Lung tissue preparation for histology and immunohistochemical studies
Lung tissue was prepared using methods described previously (Ji et al., 2007). In brief, mice 
were sacrificed, the left lung was removed and snap-frozen, while the right lung was inflated 
and fixed in buffered 10% formalin overnight. Paraffin sections were prepared, and cut at 5 
microns for hematoxylin and eosin (H&E) staining.
Apoptosis was assessed in lung cancer sections by the terminal deoxynucleotidyl transferase 
dUTP-biotin nick end labeling (TUNEL) method using ApopTag Peroxide In Situ Apoptosis 
Detection Kit (Chemicon International, Inc.). To assess cell proliferation, a rabbit polyclonal 
antibody against Ki67 (1: 2500; Vector Lab) was used. An antibody against pS6(S240/244) 
(New England Biolabs) was also used for immunohistochemistry. TUNEL-positive and 
Ki67-positive cells were each counted as the number of positive cells per high power field 
(200x) in a blinded manner. pS6(S240/244) expression was assessed on a scale from 0 to 4 
in tumors in a blinded manner, integrating both strength of the signal and uniformity among 
cells in the tumors into this score.
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In vivo rapamycin treatment
Rapamycin treatment was given by intraperitoneal (IP) injection every other day at 6mg/kg 
(Meikle et al., 2007). Rapamycin was suspended in 5% (v/v) Tween-80 and 5% (v/v) PEG 
400. In one cohort, magnetic resonance imaging (MRI) was used to assess lung tumor 
involvement before and after rapamycin or control vehicle treatments. MRI images were 
used to quantify the extent of tumor involvement using NIH ImageJ (version 1.33) as 
described previously (Li et al., 2007).
In a second survival cohort, treatment with rapamycin was initiated at 9 weeks following 
AdCre infection, and continued every other day until survival was terminated due to 
respiratory difficulties, or death.
Cell culture
Lung cancer cell lines were obtained from the ATCC by Dana-Farber Cancer Institute Lung 
Cancer Program. All cell lines were maintained in the growth medium recommended by the 
supplier.
Immunoblotting
Cell and mouse tumor lysates were prepared in lysis buffer (Cell Signaling Technology) 
supplemented with protease and phosphatase inhibitor I and II cocktails (Calbiochem), using 
a Dounce homogenizer for the tumor nodules, and clarified by centrifugation at 13,000 g for 
10 minutes.
Protein concentrations were determined using the DC Protein Assay (Bio-Rad) and 
equivalent amounts (50 μg) were subjected to SDS-PAGE on 4-12% gradient gels 
(Invitrogen), transferred to PVDF membranes and detected by immunoblotting with 
antibodies indicated using SuperSignal West Pico Chemiluminescent substrate (Pierce 
Biotechnology). Antibodies used were against: TSC1, pAKT(S473), AKT, pS6(S240/244), 
pS6(S235/236), S6, pERK(T202/Y204), ERK (Cell Signaling Technology); TSC2, (Santa 
Cruz Biotechnology, Santa Cruz, CA).
Multiplex ligation-dependent probe assay (MLPA) for analysis of TSC1/TSC2 for LOH, and 
genotyping of the Tsc1 allele in mouse samples
MLPA analysis for LOH in TSC1 and TSC2 was performed using a set of 23 homemade 
probes, consisting of 10 probes in TSC1, 10 probes in TSC2, and 3 control probes from 
different chromosomes, as described (Kozlowski et al., 2007). MLPA products were 
quantified by capillary electrophoresis on an ABI 3100 Genetic Analyzer (Applied 
Biosystems, Inc.), using GeneMapper v3.5 (ABI). Excel programs were used to transform 
the peak height data to normalized values, such that the average signal from control samples 
after normalization was 1. We classified cases as demonstrating LOH for TSC1 or TSC2 
when the average signal from probes for those genes was ≥ 0.2 lower than the average signal 
from other probes in the set, and a comparison of signal intensity was significant at a p < 
0.001 in a two sided t-test.
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To assess the genotype of mouse DNA samples from mice bearing combinations of the 
floxed (L), null (K), and wild type (W) alleles, a panel of 9 MLPA probes was generated to 
interrogate these three alleles, including 4 control probes and probes specific for each allele. 
MLPA analysis was performed on DNA samples from mice of known genotypes as controls, 
and then performed on tumor nodules to determine percent of each allele present, after 
normalization and comparison with control samples. Oligonucleotide sequences for the 
probe sets and details are available on request.
Results
KrasG12D mutation synergizes with Tsc1 loss in the bronchial epithelium to lead to 
accelerated lung cancer development and early mortality
To generate mice with both expression of KrasG12D and loss of Tsc1 in the lung epithelium, 
we crossed mice bearing the Lox-Stop-Lox KrasG12D (hereafter LSL-KrasG12D) allele 
(Jackson et al., 2001) to Tsc1L/L mice (Kwiatkowski et al., 2002). Mice bearing different 
combinations of both alleles were then treated with an adenovirus encoding the cre 
recombinase (AdCre) by nasal inhalation to induce Cre-mediated recombination in the lung 
epithelium at age 4 – 7 weeks (Figure 1A). This treatment is known to infect a small percent 
of lung bronchial epithelial cells. Following AdCre treatment, the median survival was 11.6 
weeks for LSL-KrasG12D Tsc1L/L mice, in contrast to 27.5 weeks for LSL-KrasG12D (alone) 
mice (Logrank test, p = 0.002). In addition, AdCre-treated LSL-KrasG12D Tsc1L/+ mice had 
a median survival of 15.6 weeks, which was also significantly different from both the LSL-
KrasG12D mice (p = 0.04), and the LSL-KrasG12D Tsc1L/L mice (p = 0.009). All AdCre-
treated Tsc1L/L mice survived over 50 weeks (Figure 1A).
Pathologic analysis of lung tissue demonstrated that AdCre-treated LSL-KrasG12D Tsc1L/L 
mice at 12.5 weeks post-treatment had developed multifocal adenocarcinoma with extensive 
involvement of the lung parenchyma, consistent with their progressive respiratory 
insufficiency and death (Figure 1B). Similarly, AdCre-treated LSL-KrasG12D Tsc1L/+ mice 
also showed multifocal adenocarcinoma of the lung on histological analysis at that age, but 
this was somewhat less extensive. At 12.5 weeks, AdCre-treated LSL-KrasG12D mice (with 
wild type Tsc1) had multiple microscopic foci of adenocarcinoma, that was much less 
developed, similar to previous reports (Jackson et al., 2001; Ji et al., 2007). By standard 
pathologic analysis, the lung adenocarcinomas from mice of these three genotypes were 
indistinguishable. Consistent with their extended survival, AdCre-treated Tsc1L/L mice had 
no lung tumors or other pathology when sampled at 1 year post treatment. These results 
indicate that both complete and haploid loss of Tsc1 cooperate significantly with activating 
Kras mutation to accelerate lung tumorigenesis.
Signaling analyses indicate that LSL-KrasG12D Tsc1L/L mouse lung cancers have activated 
mTORC1
Immunoblot analysis of lung tumor lysates demonstrated that Tsc1 protein levels were 
reduced in lung cancers developing in both LSL-KrasG12D Tsc1L/L and LSL-KrasG12D 
Tsc1L/+ mice in comparison to tumors from LSL-KrasG12D mice (Figure 1C). Tsc2 protein 
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levels were also correspondingly reduced, consistent with the chaperone-like effect of Tsc1 
on Tsc2 levels (Harrington et al. 2004).
Phospho-S6-S240/244 (pS6(S240/244)) levels were increased in the tumor lysates from both 
LSL-KrasG12D Tsc1L/L and LSL-KrasG12D Tsc1L/+ mice, consistent with activation of 
mTORC1 due to loss of functional Tsc1/Tsc2 in those tumors, again in contrast to tumor 
lysates from LSL-KrasG12D mice (Figure 1C). In addition, phospho-AKT-S473 
(pAKT(S473)) levels were also reduced, on average, in both LSL-KrasG12D Tsc1L/L and 
LSL-KrasG12D Tsc1L/+ mouse lung cancers when compared to LSL-KrasG12D alone lung 
tumors. This effect is well-known in a variety of cell types and systems, as a mechanism of 
feedback regulation consequent to loss of Tsc1/Tsc2 and activation of mTORC1 (Zhang et 
al., 2003; Harrington et al., 2004; Huang et al., 2008). ERK activation appeared to be higher 
in the LSL-KrasG12D alone lung tumors, as assessed by levels of pERK(T202/Y204) (Figure 
1C).
To examine the possibility that lung tumors developing in LSL-KrasG12D Tsc1L/+ mice had 
undergone genomic deletion or homologous recombination leading to loss of the Tsc1+ 
allele, we used multiplex ligation-dependent probe assay (MLPA) to investigate the copy 
number of the various alleles of Tsc1 in these tumors (Kozlowski et al., 2007). Lung tumors 
from LSL-KrasG12D Tsc1L/L mice showed a 65% (median) level of conversion of the 
conditional to the null allele, consistent with recombination at both conditional alleles in 
tumor cells, and contamination by inflammatory, stromal, and vascular cells (Fig. 1D). 
Similarly, LSL-KrasG12D Tsc1L/+ mice displayed 52% (median) conversion of the single 
conditional Tsc1 allele to the null allele. They also showed no major reduction in the copy 
number of the wild type (+) allele of Tsc1 (median 41%), suggesting that these tumors 
developed through a haploinsufficiency mechanism.
Haploid loss of TSC1 is common in human lung cancer specimens
As these results suggested that the Tsc1 gene could function as a tumor suppressor gene for 
lung cancer development in the mouse, we explored its involvement in human lung cancer. 
MLPA was used to assess TSC1 and TSC2 genomic copy number in DNA prepared directly 
from frozen lung cancer samples from 86 NSCLC patients (Figure 2) (Kozlowski et al., 
2007). Genomic loss was seen in 19% and 5% of patients, respectively, for TSC1 and TSC2 
(Figure 2A). In addition, one patient’s cancer displayed a copy number for TSC1 that was 
40%, consistent with complete deletion of TSC1 in tumor cells from this patient, considering 
stromal and inflammatory cell contamination (Figure 2B).
In summary, 22% of 86 lung cancer specimens showed evidence of TSC1 and/or TSC2 
genomic deletion by MLPA. However, the frequency of TSC2 LOH was so low, that this 
may represent genomic background copy number change, rather than a specific deletion of 
TSC2.
TSC1/TSC2 loss in human lung cancer cell lines
To explore the loss of TSC1/TSC2 in human lung cancer in greater detail, we surveyed Akt-
mTOR signaling in 80 lung cancer cell lines (Supplemental Table 1). None of the 80 cell 
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lines were found to display evidence of complete loss of TSC1 or TSC2 by immunoblotting 
(data not shown). However, 9 (11%) and 2 (3%) of the 80 cell lines showed evidence of 
LOH for TSC1 or TSC2, respectively, by MLPA analysis (Supplemental Table 1). In 
addition, some cell lines showed high levels of phospho-S6(S240/244) in the absence of 
serum. However, those same lines generally showed elevated activation of pAKT (S473), 
consistent with this effect being due to upstream activation of PI3K, PTEN loss, or other 
mutation.
Rapamycin effects in the Kras - Tsc1 mouse lung cancer model
Since rapamycin is a highly specific therapy which blocks mTORC1 through interaction 
with FKBP12 (Sabers et al., 1995), we assessed the potential benefit of rapamycin as a 
treatment for the LSL-KrasG12D Tsc1L/L mouse model. Magnetic resonance imaging (MRI) 
was used to assess tumor extent before and after a 2 week period of treatment with 
rapamycin at 6 mg/kg IP every other day (Figure 3A). LSL-KrasG12D Tsc1L/L mice showed a 
clear response to rapamycin with an average 54% reduction in tumor extent, as assessed by 
MRI (Figure 3A, 4A). LSL-KrasG12D Tsc1L/+ tumors showed a smaller response with an 
overall 13% average reduction in tumor volume, though several mice showed a much 
greater response. LSL-KrasG12D mice showed on average stable disease (2% increase) 
during this period of treatment, while LSL-KrasG12D Lkb1L/L tumors in general showed 
major progression during rapamycin treatment (average 107% increase). Note that placebo-
treated control mice of the LSL-KrasG12D Tsc1L/L and LSL-KrasG12D Lkb1L/L genotypes 
(Figure 4A squares) showed a variable but generally marked increase in tumor extent during 
two weeks of observation while a much slower growth rate was seen in placebo-treated LSL-
KrasG12D mice, consistent with their markedly different survivals (Figure 4A, 1A).
Analysis of tumor sections from the mice after 1 to 4 doses of rapamycin showed that both 
LSL-KrasG12D Tsc1L/L and LSL-KrasG12D tumors showed increased TUNEL positivity 
consistent with apoptosis after rapamycin treatment (Figure 3B, 4B). However, this was 
more pronounced in the LSL-KrasG12D Tsc1L/L mice than in the LSL-KrasG12D mice after 2 
and 4 doses of rapamycin (p=0.028 and 0.048, respectively, Figure 4B). In addition, LSL-
KrasG12D Tsc1L/L mice showed evidence of a sustained reduction in proliferation following 
2 and 4 doses of rapamycin, in contrast to LSL-KrasG12D mice, although this did not meet 
statistical significance (Figure 4C). In both types of mice there was marked reduction in 
pS6(S240/244) levels, as assessed by immunohistochemistry. pS6 (S240/244) levels were 
somewhat higher in the LSL-KrasG12D Tsc1L/L mice without treatment, but this did not meet 
statistical significance (Figure 4D).
Both LSL-KrasG12D Tsc1L/L mice and LSL-KrasG12D Tsc1L/+ mice treated with rapamycin at 
6 mg/kg IP every other day showed a significant improvement in survival (Figure 5). A 
striking improvement in survival was seen in the LSL-KrasG12D Tsc1L/L mice (median 
survival 2.9 vs. 18.6 weeks, p = 0.0018). The improvement in survival in the LSL-KrasG12D 
Tsc1L/+ mice was somewhat less dramatic but still highly significant (6.9 vs. 16.3 weeks, p = 
0.002), likely due in part to the slower tumor onset in LSL-KrasG12D Tsc1L/+ mice.
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Lung cancer is the most common cause of cancer death for both females and males in the 
US population (Jemal et al., 2008; Molina et al., 2008). In the past 10 years, the greatest 
progress in lung cancer treatment research has been in the identification of a strong 
correlation between the effectiveness of molecularly targeted therapies (erlotinib, gefitinib) 
against the EGFR tyrosine kinase and tumor genotype (activating mutation in EGFR) 
(Ciardiello & Tortora, 2008). This experience lends hope to the concept that a detailed 
molecular characterization of each lung cancer may lead to the identification of unique 
molecularly targeted treatments designed to exploit the critical oncogenic signaling in each 
tumor. Here we show that lung cancers in the mouse in which TSC1/TSC2 function is 
eliminated or reduced are uniquely sensitive to a molecularly targeted therapy (rapamycin, 
RAD001, CCI-779, etc.). However, we observed that complete loss of TSC1/TSC2 is very 
rare in the human lung cancer cell lines we studied, consistent with other recent results 
(Ding et al., 2008).
We observed major in vivo synergism between activation of Kras and haploid or complete 
loss of Tsc1 in the development of lung cancer in the mouse. Mice that were either Tsc1L/L 
or Tsc1L/+, as well as LSL-KrasG12D, developed lung cancer on exposure to AdCre at a rate 
that was 1.8-2.4-fold faster than that seen in mice with LSL-KrasG12D alone (Figure 1A). 
Although there were distinct differences in histology and metastatic behavior, their survival 
was similar to that of AdCre-treated LSL-KrasG12D Lkb1L/L mice (Ji et al., 2007). In 
addition, it was more limited than that of AdCre-treated mice bearing the LSL-KrasG12D 
allele, and conditional alleles of either p16INK4a, p53, or Ink4a/Arf (Ji et al., 2007). Both 
Tsc1L/L LSL-KrasG12D and Tsc1L/+ LSL-KrasG12D mice demonstrated unique sensitivity to 
treatment with rapamycin as a single agent, in contrast to mice with Kras activating mutation 
alone, or LSL-KrasG12D Lkb1L/L mice. Survival of both genotypes of Kras-Tsc1 mice was 
significantly prolonged in response to rapamycin treatment (Figure 5). Our observations that 
rapamycin treatment was able to cause stable disease (neither growth of tumor nor 
significant reduction) in the LSL-KrasG12D only mice is similar to a previous report in a 
different Kras lung model in which CCI-779 was given as an mTORC1 inhibitor (Wislez et 
al., 2005). In that study, high dose CCI-779 (20 mg/kg daily for 4 weeks) led to stabilization 
of lung tumor extent, with prevention of the appearance of new lung tumors, and a small 
reduction in tumor size, but mainly due to induction of apoptosis in tumor-infiltrating 
macrophages (Wislez et al., 2005).
We found that none of 80 NSCLC lines examined had a signaling pattern similar to that of 
TSC1 null or TSC2 null MEFs (Zhang et al., 2003; Harrington et al., 2004), and that all 
expressed both TSC1 and TSC2 to some extent. However, we did observe that 22% of 
human lung cancers and 14% of lung cancer cell lines displayed loss of a single allele of 
either TSC1 or TSC2 (Figure 2), similar to a previous report (Takamochi et al., 2001). This 
lack of occurrence of homozygous loss of either TSC1 or TSC2 in human lung cancer is also 
consistent with a larger body of data indicating that neither gene is a common targets for 
mutation/inactivation in human cancer. This is in striking contrast to other tumor suppressor 
genes that regulate mTOR signaling, including LKB1 which is commonly involved in lung 
cancer (Ji et al., 2007; Sanchez-Cespedes, 2007; Ding et al., 2008), and PTEN, less 
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commonly involved in lung cancer, but much more so in colon cancer and glioblastoma. 
Indeed the only common adult malignancy in which TSC1 or TSC2 loss has been reported 
to occur at appreciable frequency is bladder cancer (Hornigold et al., 1999; Adachi et al., 
2003; Platt et al., 2009). LKB1 and PTEN have broader effects beyond activation of 
mTORC1, and this may partially explain their more common involvement in adult cancers.
The reason for this discordance between lack of involvement of TSC1/TSC2 in human lung 
cancer, and a clear pathogenic role in this mouse model of lung cancer is not clear. One 
possibility is that due to their location in the genome, TSC1 and TSC2 are uncommon 
targets for genomic and mutational events. However, second hit events occur commonly in 
these genes in the tumors of TSC patients (Henske et al., 1996), arguing against a model of 
‘relative genomic protection’. A second possibility is the observation that AKT activation is 
suppressed in tumors from TSC patients, Tsc mouse model tumors, and cell lines in which 
TSC1/TSC2 is completely lost (Zhang et al., 2003; Harrington et al., 2004). This has been 
attributed to a variety of feedback mechanisms, including suppression of IRS function, 
reduced PDGFR expression, and most recently elucidation of a functional role for the TSC1/
TSC2 complex as a co-factor for the kinase activity of mTORC2, the AKT S473 kinase 
(Zhang et al., 2003; Harrington et al., 2004; Huang et al., 2008). Although this explanation 
is plausible and may contribute, one wonders why this does not occur in the mouse lung 
model studied here, in which loss of Tsc1 has a clear growth promoting effect, accelerating 
development of lung cancer. It is possible that the combination with Kras activating 
mutation and/or the timing of this combination is critical in leading to the accelerated lung 
tumor development in these mice.
The observation that haploid loss of Tsc1 in this mouse model had similar effects in 
accelerating lung tumorigenesis as complete loss (Figure 1A), is consistent with a model in 
which attenuated TSC1/TSC2 function leads to some activation of mTORC1 and 
complements KRAS mutational activation nearly as well as complete loss. The observation 
that TSC1 LOH is fairly common in NSCLC patient samples (Takamochi et al., 2001), is 
also consistent with a potential growth promoting effect of haploid expression. 
Haploinsufficiency is well-known as a growth promoting effect for a number of tumor 
suppressor genes, including PTEN, NF1, and that encoding p27Kip1 (Santarosa & 
Ashworth, 2004; Smilenov, 2006). In this mouse model, it is possible that ERK-mediated 
phosphorylation of TSC2, due to activated KRAS, synergizes with haploid loss of TSC1 to 
lead to inactivation of the TSC1/TSC2 protein complex, and mTORC1 activation (Ma et al., 
2005).
Two mTORC1 inhibitors have been used in Phase I-II clinical trials in NSCLC patients. 
Both RAD001 and CC-779 were seen to have overall a 3-5% response rate, though in one 
trial in which CCI-779 was used, this reached 8% (Gridelli et al., 2008). Two small Phase I-
II combination trials of RAD001 and gefitinib have been completed, with higher response 
rates (Milton et al., 2007), and several more are ongoing (Gridelli et al., 2008). Our data 
suggest the possibility that patients showing response might be those with haploid 
expression of TSC1/TSC2 in their lung cancers, but further study is required. Single agent 
rapamycin was quite dramatically effective in reducing tumor size (Figure 3A), and 
extending survival (Figure 5) of the LSL-KrasG12D Tsc1L/L mice, in contrast to limited or no 
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effect on the tumors of mice with Kras mutation alone or combined with Lkb1 loss. This is 
consistent with the multiple downstream targets that are influenced by Lkb1 loss (Alessi et 
al., 2006). In addition, rapamycin as a single agent has clear activity in both the renal 
epithelial tumors that develop in mouse models of TSC (Kenerson et al., 2005; Lee et al., 
2005; Pollizzi et al., 2009), and some activity in kidney angiomyolipomas that occur in TSC 
patients (Bissler et al., 2008). Thus, this additional experience in both preclinical models and 
patients supports the concept that rapamycin has particular effectiveness in tumors lacking 
functional TSC1/TSC2. Although evidently rare, lung cancers which completely lack TSC1/
TSC2 are also likely to be very sensitive to rapamycin.
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Figure 1. Loss of Tsc1 markedly accelerates oncogenic Kras-driven lung tumorigenesis in the 
mouse, with activation of mTORC1
(A) LSL-KrasG12D Tsc1L/L mice display accelerated lung cancer development and early 
mortality. Kaplan-Meier survival curves of mouse cohorts following nasal inhalation of 5 × 
106 PFU of AdCre. The median survival was 11.6 weeks for LSL-KrasG12D Tsc1L/L mice, 
15.6 weeks for LSL-KrasG12D Tsc1L/+ mice, 27.5 weeks for LSL-KrasG12D mice, and over a 
year for Tsc1L/L mice.
(B) H&E-stained sections of lung from mice 12.5 weeks following AdCre inoculation shows 
extensive tumor in both LSL-KrasG12D Tsc1L/L and LSL-KrasG12D Tsc1L/+ mice. Low 
power (left) and high power (right) views are shown. Bar, 100μm.
(C) Immunoblot analysis of protein expression and mTOR signaling in tumors from these 
mice shows that Tsc1 and Tsc2 expression is reduced in the lung tumor nodules of both 
LSL-KrasG12D Tsc1L/L and LSL-KrasG12D Tsc1L/+ mice in comparison to tumors from LSL-
KrasG12D mice. pS6(S240/244) expression is increased and pAKT(S473) expression is 
reduced, consistent with mTORC1 activation in these tumors. pERK levels are higher in the 
LSL-KrasG12D mice, compared to other genotypes. AKT, S6, ERK, and actin are all 
controls. Note that one lung tumor sample was depleted, and was not included in the Tsc2 
blot, indicated by *.
(D) MLPA analyses of Tsc1 alleles demonstrate conversion of L to K alleles in both LSL-
KrasG12D Tsc1L/L and LSL-KrasG12D Tsc1L/+ tumor nodules. Yellow, red, and blue bars 
indicate the relative amount of wild type (W), knockout (K), and conditional allele (L), 
respectively. The four samples at right (a-d) are control samples from mice with genotypes 
KW, KW, LW, and LL, respectively. Note that the W allele persists in LSL-KrasG12D Tsc1L/+ 
tumor nodules.
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Figure 2. MLPA analyses of human lung cancers identifies TSC1 and TSC2 genomic loss
(A) Summary of MLPA analyses on 86 human NSCLC specimens demonstrates the 
proportion of samples with genetic events affecting TSC1 or TSC2.
(B) MLPA graphs. a, NSCLC sample without TSC1 or TSC2 loss; b, sample with TSC1 
genomic loss, with 60% signal for all TSC1 probes; c, sample consistent with complete 
genomic deletion of TSC1, with 40% signal for 8 of 10 probes within TSC1; d, MLPA 
analysis of a control sample from a TSC patient with a heterozygous germline deletion 
involving exons 8 - 23.
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Figure 3. Rapamycin decreases tumor burden and causes apoptosis in LSL-KrasG12D Tsc1L/L 
and LSL-KrasG12D Tsc1L/+ mice
(A) MRI images (left and middle columns) of mice before and after 2 weeks of rapamycin 
treatment (6 mg/kg IP every other day). H indicates the heart. H&E stained lung tissue 
sections (right column) after 2-5 weeks of rapamycin treatment show evidence of regression 
in the LSL-KrasG12D Tsc1L/L and LSL-KrasG12D Tsc1L/+ mice. The top three H&E sections 
were from mice treated for 2 weeks, the bottom mouse was treated for 5 weeks. Bar, 100μm.
(B) Representative photographs of cancers from the LSL-KrasG12D Tsc1L/L and LSL-
KrasG12D mice showing apoptosis (TUNEL staining) without treatment, and after two doses 
of rapamycin. Bar, 100μm.
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Figure 4. Quantitative tumor response, apoptosis, proliferation, and pS6 expression in response 
to rapamycin in LSL-KrasG12D Tsc1L/L, LSL-KrasG12D, and other mice
(A) Relative change in tumor burden in mice treated with rapamycin for 2 weeks (circles). 
MRI scans from before and after treatment were assessed for tumor volume in mm3 by a 
blinded observer, and the ratio between after treatment and before treatment volumes was 
plotted. Six mice of various genotypes were placebo-treated controls in this experiment, 
shown as squares. The lines indicate average change among the treated mice.
(B) Scatter plots of number of positive cells per high power field (HPF) in lung tumor 
nodules stained to show evidence of apoptosis (TUNEL). The mice had genotypes LSL-
KrasG12D Tsc1L/L or LSL-KrasG12D, and were treated with rapamycin 6mg/kg every other 
day for 0, 1, 2, or 4 doses, as indicated on the x axis.
(C) Scatter plots of number of positive cells per HPF in lung tumor nodules stained to show 
evidence of proliferation (antibodies against Ki67), as in B.
(D) Scatter plots of relative staining intensity for pS6(S240/244) in tumor nodules from 
rapamycin-treated mice, as in B.
For B-D, all pairwise comparisons between LSL-KrasG12D Tsc1L/L and LSL-KrasG12D 
tumors after the same number of doses are not significant (P > 0.05 by Mann Whitney test), 
except for the comparison between TUNEL positivity (B) after 2 and 4 doses, p=0.028 and 
0.048 respectively.
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Figure 5. Rapamycin improves survival of LSL-KrasG12D Tsc1L/L and LSL-KrasG12D Tsc1L/+ 
mice
Kaplan-Meier survival curves of mice of two genotypes treated with either rapamycin (6 
mg/kg IP every other day) or placebo, beginning 9 weeks following AdCre inhalation. 
Rapamycin significantly extended the survival of both LSL-KrasG12D Tsc1L/L (p=0.0018) 
and LSL-KrasG12D Tsc1L/+ mice (p=0.002).
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